New pill targets brain tumors: early trial underway
NCT ID NCT06636162
First seen Mar 01, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This early-phase trial is testing an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for tumor removal surgery. The goal is to see how much of the drug reaches the brain tumor and how it affects cholesterol-related pathways in the cancer cells. Researchers will also monitor safety and side effects. This is a window-of-opportunity study, meaning participants receive the drug for a short time before their planned surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DSP-0390 (oral drug)
What this could lead to
If successful, this study could show that DSP-0390 reaches brain tumors at effective levels, pointing toward a new treatment option for IDH-mutant glioma.
What could go wrong
This is a very early, small study (20 people) focused on drug levels and safety, not on curing the disease. It may not lead to a treatment, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.